Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Research in mCRC Underscores Importance of Individualized Approach

March 5th 2020

Michael J. Overman, MD, discusses the current treatment landscape of metastatic colorectal cancer and ongoing research efforts in the space.

Dr. Khan on Retrospective Analysis of Demographics in CRC and Gastric Cancer

March 4th 2020

Amir Khan, MD, discusses a large retrospective database analysis on colorectal cancer and gastric cancer presented at the 2020 Gastrointestinal Cancers Symposium.

Dana-Farber Tackles Rising Incidence of Young-Onset Colorectal Cancer

March 3rd 2020

Dana-Farber Cancer Institute launched the Young-Onset Colorectal Cancer Center, among the first of its kind, in March 2019 to provide expert and compassionate clinical care, promote scientific discovery and innovation to elucidate underlying biological mechanisms, identify risk factors, and facilitate development of novel therapies, and improve prevention and early detection by raising public awareness of the rising burden of CRC in young adults.

Dr. Raghav on Activating the RAS/RAF/MEK/ERK Pathway in CRC

March 3rd 2020

Kanwal Raghav, MBBS, MD, discusses the activation of the RAS/RAF/MET/ERK pathway in colorectal cancer.

Breathing New Life Into Chemotherapy

March 2nd 2020

Although the development of chemotherapy-free regimens is a major thrust of oncology research, improvements to traditional cytotoxic therapy are actively being explored, with a focus on new formulations and delivery methods for agents that have been used for decades.

FDA Approvals in HCC and Cervical Cancer, Breakthrough Designation in Lung Cancer, and More

February 26th 2020

The Future of MRD Assessment in CRC

February 26th 2020

Postsurgical ctDNA Surveillance in Locally Advanced CRC

February 26th 2020

Applying MRD Testing in Locally Advanced CRC

February 26th 2020

CRC: Incorporating MRD Testing Into Routine Practice

February 26th 2020

Potential Use of ctDNA and MRD in CRC

February 26th 2020

Revolutionizing Personalized Medicine in CRC

February 26th 2020

Young Adults With CRC and Gastric Cancer Have Worse Survival, Clinical Features

February 26th 2020

Amir Ali Khan, MD, discusses the results of the database analysis and the remaining questions with young adult patients with colorectal cancer and gastric cancer.

Future Directions for Later-Line Therapy in R/R mCRC

February 25th 2020

Role of Immunotherapy in Microsatellite-Stable R/R mCRC

February 25th 2020

Relapsed/Refractory mCRC: Immunotherapy in MSI-High Tumors

February 25th 2020

Management of R/R mCRC: Sequencing for Later-Line Therapies

February 25th 2020

R/R Metastatic CRC: CORRECT, IMblaze370, and ReDOS Trials

February 25th 2020

Third-line and Later-line Therapies in R/R mCRC

February 25th 2020

Role of Rebiopsy and ctDNA Testing at Progression of mCRC

February 25th 2020